Shipra Gandhi, MD

Articles

Translating Data With Oral SERDs to Practice: EMBER-3, SERENA-2, and Ongoing Trials

January 30th 2025

Dr. Gandhi and Dr. Clifton discuss incorporating imlunestrant plus abemaciclib into treatment sequencing for hormone receptor–positive/HER2-negative (HR+/HER2–) metastatic breast cancer (BC), considering factors such as ESR1 mutation status, prior CDK4/6 inhibitor (CDK4/6i) use, and visceral metastases, while also highlighting key trials of selective estrogen receptor degraders (SERDs), including SERENA-2 and OPERA-01.

Imlunestrant Clinical Data: Insights From the EMBER and EMBER-3 Trials

January 30th 2025

Dr. Clifton and Dr. Gandhi review the EMBER trial program, discussing study designs, key findings from phase 1b and EMBER-3 trials of imlunestrant-based combinations, and insights into efficacy, safety, and subgroup outcomes in estrogen receptor–positive/HER2-negative (ER+/HER2–) advanced breast cancer (ABC).

Approved and Investigational SERDs in HR+/HER2– Breast Cancer

January 23rd 2025

Dr. Gandhi and Dr. Clifton discuss the evolving role of oral selective estrogen receptor degraders (SERDs) in the treatment paradigm for hormone receptor–positive/HER2-negative (HR+/HER2–) breast cancer, considering patient characteristics, clinical scenarios, and the landscape of approved and investigational agents, including elacestrant, imlunestrant, and camizestrant.

Endocrine Sensitivity and the Prognostic and Clinical Implications

January 23rd 2025

Dr. Gandhi and Dr. Clifton explore the prevalence and mechanisms of resistance to first-line endocrine therapy combined with CDK4/6 inhibitors in hormone receptor–positive/HER2-negative (HR+/HER2–) breast cancer.

Shifting Paradigms: Biomarker Testing and ESR1 Mutation Surveillance in HR+ HER2- Breast Cancer

January 15th 2025

Dr. Clifton and Dr. Gandhi discuss the critical role of biomarker testing, particularly ESR1 mutation surveillance, in HR+/HER2- breast cancer, and its impact on prognosis and treatment decision-making.

Dr Gandhi on Considerations for Continuing CDK4/6 Inhibitors After Progression in HR+ Advanced Breast Cancer

July 22nd 2024

Shipra Gandhi, MD, discusses considerations for continuing with a CDK4/6 inhibitor or switching therapies in HER2- negative advanced breast cancer.

Neighborhood Plays an Important Role in Clinical Outcomes for Patients With Breast Cancer

July 28th 2023

Addressing socioeconomic health disparities has been a crucial objective of health policy in the United States. The relationship between cancer incidence and mortality and socioeconomic status varies across malignancies.